TAVEXIA : PLANS RS 68 CR FUND RAISE FOR MEYONEX STAKE BUY

• Board accorded in-principle approval to raise up to ₹68 Cr in one or more tranches • Modes considered include preferential issue of securities, rights issue or any other permissible mode • Proceeds to finance proposed acquisition of 60% equity share capital of Meyonex Pharmaceuticals, approved by board on 07 Oct 2026 • Final mode, structure and terms to be approved at a subsequent board meeting • Q2 revenue from operations at ₹15.80 Cr v ₹195.98 Cr (YOY); H1 at ₹39.20 Cr v ₹317.53 Cr • RTA changed from Niche Technologies to Skyline Financial Services; effective date to be intimated Impact: Neutral (₹68 Cr raise would fund 60% Meyonex stake, but mode, dilution terms and pricing are undecided while Q2 revenue fell sharply YOY)

Tavexia Lifecare Ltd

Open attachment

← Back to feed